• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Uterine and Ovarian Cancer Trends Over the Past Two Decades: How Have Mortality Rates Changed Across Race and Ethnicity?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Giaquinto et al. (Obstetrics & Gynecology, 2022) assessed mortality trends for uterine and ovarian cancer, including analysis by race and ethnicity

METHODS:

  • Population-level study
  • Setting
    • United States, between 1990 and 2019
    • Data on uterine and ovarian cancer death rates were obtained from SEER
  • Study design
    • Cancer death rates were age-standardized to the 2000 U.S. standard population and expressed per 100,000 person-years
      • Rates were stratified by mutually exclusive racial and ethnic categories: Asian or Pacific Islander, Black, Hispanic, or White
    • The average annual percent change was calculated using regression analysis
    • Mortality rate ratio (RR) comparing uterine and ovarian cancer and racial and ethnic subpopulations with White people were calculated
  • Primary outcome
    • Uterine cancer death rates
    • Ovarian cancer death rates

RESULTS:

  • Deaths from uterine cancer: 232,957 | Deaths from ovarian cancer: 419,085
  • Ovarian cancer mortality rates per 100,000 women decreased between 1990 and 2019
    • 1990: 9.3 per 100,000 women
    • 2019: 6.0 per 100,000 women
    • 2010 to 2019 average annual percent change: −2.7% (95% CI, −3.5 to −2.0)
  • Uterine cancer mortality decreased from 1990 to 1997, but then increased by 2019
    • 1990: 4.3 per 100,000 women
    • 1997: 4.0 per 100,000 women
    • 2019: 5.1 per 100,000 women
    • 2010 to 2019 average annual percent change: 1.7% (95% CI 1.3 to 2.1%)
  • Ovarian cancer mortality decreased during the early 1990s to 2019
    • Early 1990s: 5.0 per 100,000 women
    • 2019: 0.9 per 100,000 women
  • Uterine cancer mortality rate ratio for Black compared with White women increased between 1990 and 2019 (P<0.001)
    • 1990 to 1994: RR 1.83 (95% CI, 1.77 to 1.89)
    • 2015 to 2019: R 1.98 (95% CI, 1.93 to 2.02)

CONCLUSION:

  • While in the 1990s mortality risk was 2 times higher for ovarian cancer than for uterine cancer, over the past 20 years this increased risk has mostly been eliminated by opposite mortality trends
  • Among Black women mortality disparities have widened
    • Black women face a twofold higher risk of uterine cancer mortality compared to White women, despite similar incidence
  • The authors state

…the gynecologic cancer landscape is changing rapidly, and the risk of death from uterine cancer is now similar to that for ovarian cancer among women overall and approximately 60% higher among Black women based on national mortality statistics

Learn More – Primary Sources:

The Changing Landscape of Gynecologic Cancer Mortality in the United States

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Does Assisted Reproduction Increase Risk of Breast, Ovarian, Uterine Cancer?
Do Contraceptives Decrease Risk for All Ovarian Cancers?
How Common is Unexpected Uterine Cancer at Hysterectomy?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site